www.smccro-lab.com
Open in
urlscan Pro
219.94.162.205
Public Scan
Submitted URL: https://smccro-lab.com/
Effective URL: https://www.smccro-lab.com/
Submission: On April 28 via api from US — Scanned from JP
Effective URL: https://www.smccro-lab.com/
Submission: On April 28 via api from US — Scanned from JP
Form analysis 0 forms found in the DOM
Text Content
* JP * EN * COMPANY * CSR * RECRUIT * HOME * SMC QUALITY * SERVICE * MODEL LINEUP * PUBLICATION * NEWS * COLUMN * CONTACT Our Focus on Immuno-Oncology IN THE FIELD OF IMMUNO-ONCOLOGY, THE STAM™ MOUSE IS THE MOST PATHOLOGICALLY SUITABLE MODEL FOR DEVELOPING NEW THERAPEUTIC DRUGS FOR LIVER CANCER. The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations. READ MORE NEWS RELEASE 【Breaking News!】 First MASH treatment approved by FDA On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (res… READ MORE EVENT SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japane… READ MORE Cell metab., “MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity” (Cell Metab., DOI: 10.1016/j.cmet.2022.10.007., 2022) READ MORE STAM™ model Our STAM™ model is a model that recapitulates the same disease progression as human MASH/HCC. READ MORE * 1 * 2 * 3 * 4 * 5 SERVICE Search by topics * DISEASE AREA In addition to the liver disease area that we focus on, we also provide non-clinical pharmacology studies for various other disease areas. * MECHANISM OF ACTION The STAM™ mouse is our in-house developed model. It is a MASH-HCC model with a diabetes background. So far, we have over 15 MOA categories and more than 270 target molecules of test substances that we have evaluated using STAM™ mice. * MODEL LINEUP We offer various disease mice models related to inflammation, fibrosis, metabolic disorders, cancer, or cancer immunity, as well as STAM™ model, which is a world's first MASH (metabolic dysfunction-associated steatohepatitis) mouse model that we have developed. * PUBLICATION Results of non-clinical pharmacology studies by our company have been presented at many major academic conferences in the United States and Europe, such as DDW, AASLD, EASL, ADA, or AACR. It has also been published in journals such as PNAS, Hepatology, or Cell metabolism. * PHARMACOLOGY STUDY SERVICES We are a consulting-type non-clinical CRO, meaning that we design in-vivo studies with clients’ requests. We have been supporting their cutting-edge research on non-clinical pharmacology study. * CASE STUDY Here, we can share some data for clinical correlation between the results of our non-clinical studies using STAM™ mice and the results of clinical studies. * THERAPEUTIC AREA We provide services that utilize our technology and know-how regarding inflammation, fibrosis, metabolic disorder, cancer, and cancer immunity. OUR PATENTED ORIGINAL TECHNOLOGYSTAM™ MOUSE We are contributing to the world through providing cutting-edge non-clinical pharmacology studies with our unique patented technology, the STAM™ mouse. In order to develop a new drug, it is important to be able to accurately measure the effectiveness of the drug at the non-clinical trial stage. The STAM™ mouse, a model that more accurately reflects human pathology, plays a major role for this purpose. LEARN MORE COLUMN Previous 2024.03.15 PITFALLS OF [ DISEASE MODEL MICE ] THAT RESEARCHERS UNKNOWINGLY FALL INTO. In order to evaluate your compound, rather than using a general pulmonary fibrosis model that does not match y… READ MORE 2024.03.15 | A MUST FOR IPF RESEARCHERS! | SUGGESTIONS FOR THE BEST DISEASE MODEL FOR YOUR RESEARCH If you are considering a drug efficacy study using a mouse model of lung fibrosis, you should use a model that… READ MORE 2024.04.08 【HOT DATA】 RESMETIROM (MGL-3196) EVALUATION DATA AVAILABLE IN STAMTM MODEL MASHResmetiromSTAM As you may already know, the United States Food and Drug Administration (FDA) announced the approval of Rezdif… READ MORE 2024.03.21 WHAT IS THE BEST NON-CLINICAL LIVER CANCER MODEL WITH 100% CANCER INCIDENCE RATE AND SUITABLE FOR LIVER CANCER ASSESSMENT? If you are considering a drug evaluation study for liver cancer using a mouse model, our STAMTM-HCC/IO+ model … READ MORE 2024.03.19 [ BREAKING NEWS! ] FIRST MASH TREATMENT APPROVED BY FDA On March 14th, industry-altering news was published. Do you know already what we are talking about? The United… READ MORE 2024.03.15 [EXISTING COMPOUNDS] THAT HAVE ADVANCED TO CLINICAL TRIALS WILL ACCELERATE THE LAUNCH OF YOUR DRUGS. If you are planning to launch your therapeutic drug, you should select disease mouse models that have shown ac… READ MORE 2024.03.15 PITFALLS OF [ DISEASE MODEL MICE ] THAT RESEARCHERS UNKNOWINGLY FALL INTO. In order to evaluate your compound, rather than using a general pulmonary fibrosis model that does not match y… READ MORE 2024.03.15 | A MUST FOR IPF RESEARCHERS! | SUGGESTIONS FOR THE BEST DISEASE MODEL FOR YOUR RESEARCH If you are considering a drug efficacy study using a mouse model of lung fibrosis, you should use a model that… READ MORE 2024.04.08 【HOT DATA】 RESMETIROM (MGL-3196) EVALUATION DATA AVAILABLE IN STAMTM MODEL MASHResmetiromSTAM As you may already know, the United States Food and Drug Administration (FDA) announced the approval of Rezdif… READ MORE 2024.03.21 WHAT IS THE BEST NON-CLINICAL LIVER CANCER MODEL WITH 100% CANCER INCIDENCE RATE AND SUITABLE FOR LIVER CANCER ASSESSMENT? If you are considering a drug evaluation study for liver cancer using a mouse model, our STAMTM-HCC/IO+ model … READ MORE 2024.03.19 [ BREAKING NEWS! ] FIRST MASH TREATMENT APPROVED BY FDA On March 14th, industry-altering news was published. Do you know already what we are talking about? The United… READ MORE 2024.03.15 [EXISTING COMPOUNDS] THAT HAVE ADVANCED TO CLINICAL TRIALS WILL ACCELERATE THE LAUNCH OF YOUR DRUGS. If you are planning to launch your therapeutic drug, you should select disease mouse models that have shown ac… READ MORE 2024.03.15 PITFALLS OF [ DISEASE MODEL MICE ] THAT RESEARCHERS UNKNOWINGLY FALL INTO. In order to evaluate your compound, rather than using a general pulmonary fibrosis model that does not match y… READ MORE 2024.03.15 | A MUST FOR IPF RESEARCHERS! | SUGGESTIONS FOR THE BEST DISEASE MODEL FOR YOUR RESEARCH If you are considering a drug efficacy study using a mouse model of lung fibrosis, you should use a model that… READ MORE Next * 1 * 2 * 3 * 4 * 5 * 6 VIEW MORE MODEL LINEUP We can introduce disease mice models related to inflammation, fibrosis, metabolic disorder, cancer, and cancer immunity, including the STAM™ mouse, the world's first MASH model mouse developed in our company. STAM™ MODEL DISEASE AREAMASH/NASH-HCCTHERAPEUTIC AREAS LEARN MORE BLEOMYCIN-INDUCED PULMONARY FIBROSIS MODEL DISEASE AREAIPFTHERAPEUTIC AREAS LEARN MORE PORCINE PANCREATIC ELASTASE (PPE) MODEL COPDDISEASE AREATHERAPEUTIC AREAS LEARN MORE CCL4-INDUCED LIVER FIBROSIS MODEL CirrhosisDISEASE AREATHERAPEUTIC AREAS LEARN MORE BILE DUCT LIGATION (BDL) MODEL DISEASE AREAPBCTHERAPEUTIC AREAS LEARN MORE TAA-INDUCED ACUTE LIVER FAILURE MODEL ALFDISEASE AREATHERAPEUTIC AREAS LEARN MORE VIEW MORE NEW STAGE We can introduce disease mice models related to inflammation, fibrosis, metabolic disorder, cancer, and cancer immunity, including the STAM™ mouse, the world's first MASH model mouse developed in our company. LEARN MORE COMPANY At SMC Laboratories, we support drug research with our cutting-edge non-clinical pharmacology studies to quickly deliver therapeutic drugs to patients suffering from diseases that cannot be treated with existing drugs. LEARN MORE PUBLICATION At SMC Laboratories, we support drug research with our cutting-edge non-clinical pharmacology studies to quickly deliver therapeutic drugs to patients suffering from diseases that cannot be treated with existing drugs. * List of publications Published papers PNAS, Oncotarget, Hepatology, Plos One etc. * List of presentations Published presentation DDW, AASLD, EASL, AACR etc. NEWS Previous 2024.03.08 PRODUCTS AND SERVICE 【CASE STUDY】WHY DO DISEASE MODEL MICE CHANGE THE OUTCOMES? If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of … READ MORE 2024.03.05 PRODUCTS AND SERVICE INTRODUCTION OF [PATHWAY MAP OF MASH COMPOUNDS] TO ACCELERATE YOUR RESEARCH When conducting non-clinical research, it is important to choose an appropriate mouse model that reproduces hu… READ MORE 2024.04.10 EVENT SMC WILL BE EXHIBITING AT THE 110TH GENERAL MEETING OF THE JAPANESE SOCIETY OF GASTROENTEROLOGY We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japane… READ MORE 2024.03.22 NEWS RELEASE 【BREAKING NEWS!】 FIRST MASH TREATMENT APPROVED BY FDA On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (res… READ MORE 2024.03.14 PRODUCTS AND SERVICE WHAT IS THE BEST NON-CLINICAL LIVER CANCER MODEL WITH 100% CANCER INCIDENCE RATE AND SUITABLE FOR LIVER CANCER ASSESSMENT? If you are considering a drug evaluation study for liver cancer using a mouse model, our STAM™-HCC/IO⁺ m… READ MORE 2024.03.12 PRODUCTS AND SERVICE THE [OPTIMAL DISEASE MODEL] THAT MAXIMIZES YOUR RESEARCH OUTPUTS. The bleomycin-induced pulmonary fibrosis mouse model is commonly used to replicate the pathogenesis of IPF in … READ MORE 2024.03.08 PRODUCTS AND SERVICE 【CASE STUDY】WHY DO DISEASE MODEL MICE CHANGE THE OUTCOMES? If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of … READ MORE 2024.03.05 PRODUCTS AND SERVICE INTRODUCTION OF [PATHWAY MAP OF MASH COMPOUNDS] TO ACCELERATE YOUR RESEARCH When conducting non-clinical research, it is important to choose an appropriate mouse model that reproduces hu… READ MORE 2024.04.10 EVENT SMC WILL BE EXHIBITING AT THE 110TH GENERAL MEETING OF THE JAPANESE SOCIETY OF GASTROENTEROLOGY We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japane… READ MORE 2024.03.22 NEWS RELEASE 【BREAKING NEWS!】 FIRST MASH TREATMENT APPROVED BY FDA On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (res… READ MORE 2024.03.14 PRODUCTS AND SERVICE WHAT IS THE BEST NON-CLINICAL LIVER CANCER MODEL WITH 100% CANCER INCIDENCE RATE AND SUITABLE FOR LIVER CANCER ASSESSMENT? If you are considering a drug evaluation study for liver cancer using a mouse model, our STAM™-HCC/IO⁺ m… READ MORE 2024.03.12 PRODUCTS AND SERVICE THE [OPTIMAL DISEASE MODEL] THAT MAXIMIZES YOUR RESEARCH OUTPUTS. The bleomycin-induced pulmonary fibrosis mouse model is commonly used to replicate the pathogenesis of IPF in … READ MORE 2024.03.08 PRODUCTS AND SERVICE 【CASE STUDY】WHY DO DISEASE MODEL MICE CHANGE THE OUTCOMES? If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of … READ MORE 2024.03.05 PRODUCTS AND SERVICE INTRODUCTION OF [PATHWAY MAP OF MASH COMPOUNDS] TO ACCELERATE YOUR RESEARCH When conducting non-clinical research, it is important to choose an appropriate mouse model that reproduces hu… READ MORE Next * 1 * 2 * 3 * 4 * 5 * 6 VIEW MORE CONTACT US Page HOME SMC Laboratories Inc. Technoport Kamata Center Bldg. 2-16-1 Minami-Kamata Ota-City Tokyo, 144-0035 Japan TEL+81-3-6715-9101 LA Office（USA） 20250 Acacia St. STE 240 Newport Beach,CA 92660 TEL+1-949-756-8500 * HOME * COMPANY * CSR * RECRUIT * CONTACT * SMC QUALITY CRO CONSULTANT PATENTS CASE STUDY * SMC QUALITY CRO CONSULTANT PATENTS CASE STUDY * SERVICE CRO & CONSULTING SERVICE INFO HISTOLOGY TRIAL * MODEL LINEUP * PUBLICATION PUBLICATIONS PRESENTATIONS * NEWS EVENT NEWS RELEASE PRODUCTS AND SERVICE PUBLICATION UPDATE * COLUMN * PUBLICATION PUBLICATIONS PRESENTATIONS * NEWS EVENT NEWS RELEASE PRODUCTS AND SERVICE PUBLICATION UPDATE * COLUMN © 2024 SMC Laboratories,Inc.